No more is Myelofibrosis a threatening disorder. After so many years of research and waiting, the researchers have been able to incept a medication that can treat this rare bone disorder known as Myelofibrosis. The FDA (Food And Drug Administration) has never before approved any medication to treat this disorder. Jakafi (Ruxolitinbin) is the first successful medication that is approved by the necessary standard boards to treat the same.
Jakafi manufactured by Incyte Corporation has to be consumed twice a day. This Incyte Corporation has its partnership with Swiss Drugmaker Novartis.
Myelofibrosis is this bone disorder where one has scares instead of the marrow that has to be present. This means the body is unable to produce the necessary blood cells. One is prone to problems like anemia and any sort of other infections in the body. One can also suffer from extrameddulary hematopoiesis. Though there is no particular cause of this severe disorder, it can result because of leukemia or lymphoma.
Richard Pazdur who is the Director of the Office of Hematology and Oncology Products in the FDA Department has been appreciating the process of the invention of this medication where it is based on the process of understanding of disorder and the problems that the sufferer undergoes. generic viagra
This medication was out on a comparative study along with the placebo effect and other sorts of therapy like hydroxyureo. Jakafi however proved to be successful amongst all with patients experiencing 50% better results. Though like every medication, Jakafi can also have its own list of adverse effects including nausea, fatigue and thrombocytopenia.
No comments:
Post a Comment